http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11059787-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db5bac3b16721005f52e9b3932316fbe |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-48 |
| filingDate | 2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81f02f394776b2c13af0da67725a07d7 |
| publicationDate | 2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11059787-B2 |
| titleOfInvention | Crystalline form of lenvatinib mesylate and methods thereof |
| abstract | The present invention provides a novel crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (i.e., lenvatinib mesylate) and pharmaceutical compositions thereof. Methods of preparing such a crystalline form and uses in treatment are also provided. |
| priorityDate | 2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.